Risedronate ‘poses higher risk of fracture’ than alendronate during drug holiday
Patients may require closer monitoring two years after pausing treatment, researchers say
Risedronate users have a higher risk of hip fractures during recommended drug holidays than those given alendronate, a large study finds.
Although the absolute risk of fracture is still relatively low among recipients of oral bisphosphonates, the authors noted a distinct divergence in risk about two years after pausing therapy.
